Urigen N.A., Inc. Engages Sichenzia Ross Friedman Ference LLP

BURLINGAME, Calif., Dec 21, 2006 (BUSINESS WIRE) —
Urigen N.A., Inc. has engaged the law firm, Sichenzia Ross Friedman Ference LLP, to represent the Company in connection with its merger transaction with Valentis Inc. (NASDAQ: VLTS).

“We are pleased to be working with a law firm with the breadth of experience and demonstrated historical success of SRFF,” said William J. Garner, President and Chief Executive Officer of Urigen. “Sichenzia Ross Friedman Ference will primarily focus on completion of the merger including future reporting and NASDAQ listing requirements.”

Sichenzia Ross Friedman Ference LLP represents companies in all matters involving the securities industry, as well as in all general corporate and litigation matters. The firm is headquartered in New York.

About Urigen N.A., Inc.

Urigen N.A., Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen has five programs in development that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for the treatment of Chronic Pelvic Pain (CPP); U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting acute urethral discomfort; and U302, targeting urethritis. For further information, please visit the Company’s website at www.urigen.com.